GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

Shares of GSK PLC GSK rose 1.40% to £14.80 Monday, on what proved to be an all-around favorable trading session for the stock ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over ...

Reuters noted that a GSK spokesperson stated that the ruling “does not affect our ability to launch and market Arexvy globally, including in the UK.” The company remains confident in the validity of ...

GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn and winter is too ...

The company is committing to make at least 2 million doses of its long-acting PrEP therapy available in low- and middle-income countries next year and in 2026.

GSK, with its diversified portfolio, therefore reaches more physicians than any other company in the market. "GSK maintains a relatively large field force, reaching the majority of physicians in a ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

East Donegal Township is considering a tax break that would benefit an expansion of the GSK vaccine packaging facility in ...

The companies will use the funds to fill vials and pre-filled syringes with stockpiled vaccine ingredients, aimed at raising ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...